Skip to main content

Advertisement

SpringerLink
Log in

A functional NQO1 609C>T polymorphism and risk of hepatocellular carcinoma in a Chinese population

  • Research Article
  • Published:
Tumor Biology

Abstract

NAD(P)H:quinone oxidoreductase 1 (NQO1) is a cytosolic flavoprotein that catalyzes the two-electron reduction of quinoid compounds into hydroquinones, thus protecting cells from oxidative damage. A single base substitution (C→T) polymorphism at 609 in the NQO1 gene reduces quinone reductase activity. Thus, the lack of enzymatic activity in the homozygous C609T NQO1 polymorphism (rs1800566) may play a pivotal role in tumor development. We hypothesized that a genetic variant in NQO1 may modify individual susceptibility to hepatocellular carcinoma (HCC). To test this hypothesis that the variant may play a role in HCC susceptibility, we conducted a hospital-based case–control study of 476 HCC patients and 526 cancer-free controls in a Chinese population. The matrix-assisted laser desorption/ionization time-of-flight mass spectrometry method was performed to detect the polymorphism. The results showed that the variant alleles and genotypes of NQO1 C609T were more common among cases than those among controls (P = 0.003 and P = 0.024). Compared with the NQO1 609CC genotype, there was a significantly greater risk of HCC associated with the variant NQO1 609TT [adjusted odds ratio (OR) = 1.60, 95 % confidence interval (CI) = 1.12–2.28] and combined NQO1 609TC/TT (adjusted OR = 1.37, 95 % CI = 1.04–1.80) genotypes. Moreover, when subgroup analyses were performed, we found that the increase in risk was more evident among younger subjects, men, HbsAg-positive individuals, never smokers, never drinkers, and subjects without family history of cancer. These results suggest that the presence of the NQO1 C609T polymorphism may be a marker of genetic susceptibility to HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Abbreviations

NQO1:

NAD(P)H:quinone oxidoreductase 1

HCC:

Hepatocellular carcinoma

HBV:

Hepatitis B virus

OR:

Odds ratio

CI:

Confidence interval

SNP:

Single nucleotide polymorphisms

HWE:

Hardy–Weinberg equilibrium

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.

    Article  PubMed  Google Scholar 

  2. Farazi PA, Depinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev. 2006;6:674–87.

    Article  CAS  Google Scholar 

  3. Yuen MF, Hou JL, Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol. 2009;24:346–53.

    Article  PubMed  Google Scholar 

  4. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2:533–43.

    Article  PubMed  CAS  Google Scholar 

  5. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008;48:2047–63.

    Article  PubMed  CAS  Google Scholar 

  6. Chen CJ, Chen DS. Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: multistage hepatocarcinogenesis with multifactorial etiology. Hepatology. 2002;36:1046–9.

    Article  PubMed  Google Scholar 

  7. Nissen NN, Martin P. Hepatocellular carcinoma: the high-risk patient. J Clin Gastroenterol. 2002;35(5 Suppl2):S79–85.

    Article  PubMed  CAS  Google Scholar 

  8. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature. 2005;436:946–52.

    Article  PubMed  CAS  Google Scholar 

  9. Kato N, Ji G, Wang Y, et al. Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C. Hepatology. 2005;42:846–53.

    Article  PubMed  CAS  Google Scholar 

  10. Kim YJ, Lee HS. Single nucleotide polymorphisms associated with hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Intervirology. 2005;48:10–5.

    Article  PubMed  CAS  Google Scholar 

  11. Joseph P, Long DJ, Klein-Szanto AJ, Jaiswal AK. Role of NAD(P)H:quinone oxidoreductase 1 (DT diaphorase) in protection against quinone toxicity. Biochem Pharmacol. 2000;60:207–14.

    Article  PubMed  CAS  Google Scholar 

  12. Iskander K, Jaiswal AK. Quinone oxidoreductases in protection against myelogenous hyperplasia and benzene toxicity. Chem Biol Interact. 2005;153–154:147–57.

    Article  PubMed  Google Scholar 

  13. Siegel D, Gustafson DL, Dehn DL, et al. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. Mol Pharmacol. 2004;65:1238–47.

    Article  PubMed  CAS  Google Scholar 

  14. Dinkova-Kostova AT, Talalay P. NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch Biochem Biophys. 2010;501:116–23.

    Article  PubMed  CAS  Google Scholar 

  15. Asher G, Tsvetkov P, Kahana C, Shaul Y. A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. Genes Dev. 2005;19:316–21.

    Article  PubMed  CAS  Google Scholar 

  16. Asher G, Lotem J, Kama R, Sachs L, Shaul Y. NQO1 stabilizes p53 through a distinct pathway. Proc Natl Acad Sci U S A. 2002;99:3099–104.

    Article  PubMed  CAS  Google Scholar 

  17. Asher G, Lotem J, Sachs L, Kahana C, Shaul Y. Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1. Proc Natl Acad Sci U S A. 2002;99:13125–30.

    Article  PubMed  CAS  Google Scholar 

  18. Nioi P, Hayes JD. Contribution of NAD(P)H:quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription factors. Mutat Res. 2004;555:149–71.

    Article  PubMed  CAS  Google Scholar 

  19. Rauth AM, Goldberg Z, Misra V. DT-diaphorase: possible roles in cancer chemotherapy and carcinogenesis. Oncol Res. 1997;9:339–49.

    PubMed  CAS  Google Scholar 

  20. Rosvold EA, McGlynn KA, Lustbader ED, Buetow KH. Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics. 1995;5:199–206.

    Article  PubMed  CAS  Google Scholar 

  21. Traver RD, Siegel D, Beall HD, et al. Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer. 1997;5:69–75.

    Article  Google Scholar 

  22. Siegel D, McGuinness SM, Winski, et al. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics. 1999;9:113–21.

    Article  PubMed  CAS  Google Scholar 

  23. Misra V, Grondin A, Klamut HJ, et al. Assessment of the relationship between genotypic status of a DT-diaphorase point mutation and enzymatic activity. Br J Cancer. 2000;83:998–1002.

    Article  PubMed  CAS  Google Scholar 

  24. Kuehl BL, Paterson JW, Peacock JW, et al. Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. Br J Cancer. 1995;72:555–61.

    Article  PubMed  CAS  Google Scholar 

  25. Zhang JH, Li Y, Wang R, et al. NQO1 C609T polymorphism associated with esophageal cancer and gastric cardiac carcinoma in North China. World J Gastroenterol. 2003;9:1390–3.

    PubMed  CAS  Google Scholar 

  26. van der Logt EM, Bergevoet SM, Roelofs HM, et al. Role of epoxide hydrolase, NAD(P)H:quinone oxidoreductase, cytochrome P450 2E1 or alcohol dehydrogenase genotypes in susceptibility to colon cancer. Mutat Res. 2006;593:39–49.

    Article  PubMed  Google Scholar 

  27. Menzel HJ, Sarmanova J, Soucek P, et al. Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. Br J Cancer. 2004;90:1989–94.

    Article  PubMed  CAS  Google Scholar 

  28. Schulz WA, Krummeck A, Rosinger I, et al. Increased frequency of a null-allele for NAD(P)H:quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics. 1997;7:235–9.

    Article  PubMed  CAS  Google Scholar 

  29. Long 2nd DJ, Waikel RL, Wang XJ, et al. NAD(P)H:quinone oxidoreductase 1 deficiency increases susceptibility to benzo(a)pyrene-induced mouse skin carcinogenesis. Cancer Res. 2000;60:5913–5.

    PubMed  CAS  Google Scholar 

  30. Long 2nd DJ, Waikel RL, Wang XJ, Roop DR, Jaiswal AK. NAD(P)H:quinone oxidoreductase 1 deficiency and increased susceptibility to 7,12-dimethylbenz[a]-anthracene-induced carcinogenesis in mouse skin. J Natl Cancer Inst. 2001;93:1166–70.

    Article  PubMed  CAS  Google Scholar 

  31. Akkiz H, Bayram S, Bekar A, et al. No association of NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and risk of hepatocellular carcinoma development in Turkish subjects. Asian Pac J Cancer Prev. 2010;11:1051–8.

    PubMed  Google Scholar 

  32. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6:674–87.

    Article  PubMed  CAS  Google Scholar 

  33. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.

    Article  PubMed  CAS  Google Scholar 

  34. Nebert DW, Roe AL, Vandale SE, et al. NAD(P)H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. Genet Med. 2002;4:62–70.

    Article  PubMed  CAS  Google Scholar 

  35. Iizuka N, Oka M, Yamada-Okabe H, et al. Comparison of gene expression profiles between hepatitis Bvirus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res. 2002;62:3939–44.

    PubMed  CAS  Google Scholar 

  36. Asher G, Lotem J, Cohen B, et al. Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc Natl Acad Sci U S A. 2001;98:1188–93.

    Article  PubMed  CAS  Google Scholar 

  37. Gong X, Kole L, Iskander K, et al. NRH:quinone oxidoreductase 2 and NAD(P)H:quinone oxidoreductase 1 protect tumor suppressor p53 against 20s proteasomal degradation leading to stabilization and activation of p53. Cancer Res. 2007;67:5380–8.

    Article  PubMed  CAS  Google Scholar 

  38. Long 2nd DJ, Gaikwad A, Multani A, et al. Disruption of the NAD(P)H:quinone oxidoreductase 1 (NQO1) gene in mice causes myelogenous hyperplasia. Cancer Res. 2002;62:3030–6.

    PubMed  CAS  Google Scholar 

  39. Hamajima N, Matsuo K, Iwata H, et al. NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol. 2002;7:103–8.

    PubMed  CAS  Google Scholar 

  40. Begleiter A, Norman A, Leitao D, et al. Role of NQO1 polymorphisms as risk factors for squamous cell carcinoma of the head and neck. Oral Oncol. 2005;41:927–33.

    Article  PubMed  CAS  Google Scholar 

  41. Soucek P, Sarmanova J, Kristensen VN, et al. Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin’s and non-Hodgkin’s lymphomas. Int Arch Occup Environ Health. 2002;75:S86–92.

    Article  PubMed  CAS  Google Scholar 

  42. Kiyohara C, Yoshimasu K, Takayama K, et al. NQO1, MPO, and the risk of lung cancer: a HuGE review. Genet Med. 2005;7:463–78.

    Article  PubMed  CAS  Google Scholar 

  43. Sarbia M, Bitzer M, Siegel D, et al. Association between NAD(P)H: quinoneoxidoreductase 1 (NQO1) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract. Int J Cancer. 2003;107:381–6.

    Article  PubMed  CAS  Google Scholar 

  44. Liu Y, Zhang D. The NQO1 C609T polymorphism and risk of lung cancer: a meta-analysis. Asian Pac J Cancer Prev. 2011;12:3091–5.

    PubMed  Google Scholar 

  45. Wang Z, Hu J, Zhong J. Meta-analysis of the NAD(P)H: quinine oxidoreductase 1 gene 609 C>T polymorphism with esophageal cancer risk. DNA Cell Biol. 2012;31:560–7.

    Article  PubMed  Google Scholar 

  46. Wang X, Zhang X, Qiu B, et al. MDM2 SNP309T>G polymorphism increases susceptibility to hepatitis B virus-related hepatocellular carcinoma in a northeast Han Chinese population. Liver Int. 2012;32:1172–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (no. 81172372 and no. 30901720) and Ph.D. Programs Foundation of Ministry of Education of China (no. 20090181120111).

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Division of Liver Transplantation, Department of Liver and Vascular Surgery, West China Hospital, Sichuan University, 37 Guo Xue Road, Chengdu, 610041, Sichuan Province, China

    Fei Liu, Yonggang Wei, Wentao Wang, Bo Li, Lvnan Yan & Tianfu Wen

  2. Department of Clinical Immunological Laboratory, West China Hospital, Sichuan University, Chengdu, 610041, China

    Limei Luo

Authors
  1. Fei Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Limei Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yonggang Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wentao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bo Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lvnan Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tianfu Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yonggang Wei.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liu, F., Luo, L., Wei, Y. et al. A functional NQO1 609C>T polymorphism and risk of hepatocellular carcinoma in a Chinese population. Tumor Biol. 34, 47–53 (2013). https://doi.org/10.1007/s13277-012-0509-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-012-0509-x

Keywords

Search

Navigation